You are here: Industry Insights > antibacterial

News List

Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections PharmaSources
October 14, 2024
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections.
FDA finalises guidance, ‘Limited Population Pathway for Antibacterial and Antifungal Drugs’ expresspharma
August 07, 2020
This guidance is intended to assist sponsors in developing labelling, including prescribing information, patient labelling, and carton/container labelling for drugs approved under the LPAD pathway.
Could Antibacterial Triclosan Weaken Women's Bones? drugs
June 26, 2019
Could Antibacterial Triclosan Weaken Women's Bones?
FDA expands label for Allergan’s antibacterial Avycaz By Allie Nawrat pharmaceutical-technology
March 20, 2019
FDA expands label for Allergan's Avycaz to include children with cIAI's and cUTI's. Credit: Shutterstock.
Omadacycline similar to commonly-used antibiotics for treating pneumonia, skin infections europeanpharmaceuticalreview
February 13, 2019
Findings of two phase III, double-blind, randomised clinical trials comparing omadacycline with standard antibiotics have been published in the New England Journal of Medicine
Hidden Dangers in Dust drugs
December 12, 2018
An antibacterial called triclosan is common in dust and could result in dust-dwelling bacteria becoming antibiotic-resistant, researchers report......
Antibacterial drugs market to be worth US$51 billion by 2025 pharmaasia
December 28, 2017
Global antibacterial drugs market to gain impetus from strategic collaborations among leading enterprises, says research.
Levofloxacin still Got it? en-cphi.cn
December 08, 2017
The market performance of levofloxacin was eye-catching after marketing owing to its strong antibacterial action, good efficacy, and small side effects, etc., with the sales continuing to grow and the product rapidly becoming a star product on Chinese and
The Medicines Co. nets $400M nod for UTI antibacterial treatment fiercepharma
August 31, 2017
Vabomere's peak sales will hit $400 million in 2028, one analyst predicts.